Overview of Ticard

Property	Description
Active ingredient	Ticlopidine (Hydrochloride)
Form	Tablet (Film-coated)
Pharmacological class	Platelet Aggregation Inhibitor
Common use	Prevention of internal blood clots (thrombi)
Origin	Synthetic (Thienopyridine derivative)

What Type of Medicine is Ticard?

Ticard is a prescription-only medication belonging to the pharmacological class of Platelet Aggregation Inhibitors, widely known as antiplatelet agents. Its active substance is Ticlopidine (Ticlopidine Hydrochloride), a synthetic compound classified chemically as a Thienopyridine derivative. This drug is administered orally, typically as a film-coated tablet.

Ticlopidine is clinically recognized for its distinct, targeted action on blood platelets, differentiating it from traditional anticoagulants and earlier antiplatelet agents like Aspirin. The compound is considered a first-generation thienopyridine and, while highly effective, is often reserved as a second-line therapy for patients who cannot tolerate or have had insufficient response to other options.

What is the General Purpose of Ticlopidine?

The primary purpose of Ticlopidine is to help reduce the risk associated with dangerous vascular blockages by stopping blood platelets from sticking together. This action is essential for preventing the formation of pathological blood clots (thrombi) inside arteries.

Its function demonstrates the capacity to reduce the incidence of further thrombotic events, stroke, or vascular death. This means that the medicine offers sustained protection against blockages that could otherwise lead to serious vascular incidents, particularly in patients with a history of cerebrovascular thrombosis.

Ticlopidine’s Unique Action as a Prodrug

The fact that Ticlopidine is a prodrug is fundamental to its pharmacological identity; the substance ingested is biologically inactive and requires metabolic transformation in the liver to generate its effective form. This required activation step is critical, as the resulting active form irreversibly blocks a specific receptor on the platelet surface, causing the sustained antiplatelet effect. This unique requirement for hepatic processing is a key characteristic of the thienopyridine class and influences the time required for the drug to achieve its maximum therapeutic effect.

Regulatory References

What side effects are possible with Ticard?

Possible side effects and safety information

This summary presents the officially documented side effects and safety information for this class of medicine, as outlined in governmental regulatory documents such as the FDA and EMA prescribing information. Adverse reactions are classified by frequency based on clinical trial data.

Adverse Reaction Category	Frequency Classification	System-Organ Class Involved
Bleeding Events	Very Common / Common	Blood and Lymphatic System, Vascular Disorders
Dyspnea	Common	Respiratory, Thoracic and Mediastinal Disorders
Headache	Common	Nervous System Disorders
Diarrhea, Nausea	Common	Gastrointestinal Disorders
Hyperuricemia	Common	Metabolism and Nutrition Disorders
Rash, Hypersensitivity	Uncommon	Skin and Subcutaneous Tissue Disorders, Immune System Disorders

Serious and Clinically Significant Adverse Reactions

The most serious safety consideration is the Risk of Significant Bleeding. Like other antiplatelet agents, this medicine can cause significant, sometimes fatal, bleeding. Clinically significant bleeding events observed in regulatory trials include major gastrointestinal bleeding, traumatic bleeding, and the risk of intracranial hemorrhage (bleeding in the brain).

Safety-Related Restrictions or Limitations

Contraindications: Use is restricted in patients with a history of intracranial hemorrhage or active pathological bleeding.
Surgical Risk: The medicine must not be initiated in patients scheduled for urgent coronary artery bypass graft (CABG) surgery.
Hepatic Impairment: Use should be avoided or approached with particular caution in patients with severe hepatic impairment, due to the likely increase in drug exposure.

Population-Specific Safety Considerations

Safety data in clinical trials typically exclude certain populations. Safety has not been definitively established for patients with severe kidney disease requiring dialysis or those with recent severe bradyarrhythmia.

Safety Monitoring Notes

Healthcare professionals are required to monitor patients for signs of bleeding and potential hypersensitivity reactions. Dyspnea (shortness of breath) is often reported more frequently with this medicine compared to control agents in studies, but it is typically self-limiting and does not require discontinuation of treatment in most cases.

Overdose and Emergency Response

The official regulatory documents detail specific acute manifestations associated with Ticlopidine overdose and outline required emergency actions due to the drug’s potential for severe, life-threatening complications.

Documented Manifestations

Feature	Official Regulatory Statement
Acute Symptoms	Manifestations observed in acute overdose have included gastrointestinal hemorrhage, convulsions, hypothermia, dyspnea, loss of equilibrium, and abnormal gait.
Serious Outcomes	The primary life-threatening concerns are Thrombotic Thrombocytopenic Purpura (TTP), Neutropenia, and severe hemorrhagic events, including potential intracranial bleeding.

Required Emergency Actions

Immediate medical help must be sought for any suspected overdose or upon the onset of signs consistent with the drug’s severe complications. Regulatory guidance mandates that patients or caregivers immediately contact their physician or a poison control center for instruction.

If life-threatening hematological sequelae like TTP or Neutropenia are suspected, the drug must be discontinued immediately. Treatment for overdose is symptomatic and supportive. No specific antidote is known; however, specific procedures, such as plasmapheresis for TTP, are officially described for managing related severe complications. Close monitoring of vital signs and hematological status is required during emergency management.

Therapeutic Uses of Ticard

Quick Facts

Ticard is used to assist in reducing the potential for a first-time myocardial infarction or stroke in individuals diagnosed with coronary artery disease (CAD) who are at elevated risk for these events.
It is also employed to support the management of individuals with a history of myocardial infarction or acute coronary syndrome (ACS) to lessen the potential for another cardiac event or stroke.
The medication is utilized to help reduce the potential for blood clot formation in patients who have received a stent for ACS.

What Ticard Treats: Main Uses and Benefits

Ticard is a prescribed medication indicated for use in the cardiovascular setting. Its primary therapeutic domain is to assist in reducing the potential for certain serious cardiovascular events.

This medication is utilized for the following therapeutic applications:

Acute Coronary Syndrome (ACS) and History of Heart Attack: Ticard is intended to help lessen the potential for myocardial infarction, stroke, and cardiovascular death in individuals who have experienced ACS or who have a history of a heart attack. It is often administered in combination with low-dose aspirin as part of a comprehensive management plan.
Coronary Artery Disease (CAD): It is also employed as part of a strategy to reduce the potential for a first myocardial infarction or stroke in high-risk individuals diagnosed with stable CAD. The goal of therapy is to modulate platelet activity to support the maintenance of blood flow and reduce the potential for thrombotic events.
Stroke and TIA: The medication may be used to assist in reducing the potential for a subsequent stroke or death in patients with acute ischemic stroke or high-risk transient ischemic attack (TIA).

Therapy is overseen by a qualified healthcare professional and forms one component of a larger treatment strategy.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Ticard — Official Regulatory Information

Official regulatory documents define strict eligibility criteria for the use of Ticard. The primary exclusion groups are those where risk is formally documented to outweigh benefit, or where safety is not established.

Classification	Status and Restriction	Basis in Regulatory Label
Contraindicated Populations	Must not be used in individuals with a known severe hypersensitivity to Ticard or its components.	Absolute exclusion based on documented risk.
Pregnancy/Lactation	Contraindicated in pregnancy (especially second and third trimesters) due to risk of fetal toxicity. Use is not recommended in nursing mothers.	Prohibited status based on specific life stages.
Pediatric Use	Safety and effectiveness not established in the pediatric population (children and adolescents).	Exclusion due to insufficient clinical data.
Condition-Based Limits	Use is prohibited in diabetic patients when co-administered with medications containing aliskiren.	Exclusion based on specific, high-risk drug combinations.
Organ Function	Use requires caution and may be restricted or not recommended in patients with severe hepatic or renal impairment.	Limitation based on altered drug elimination/metabolism.

Age-Related Eligibility: Use is established for adults, but older adults (geriatric patients) require careful monitoring due to potential age-related changes in organ function. Regulatory labels strictly define who can use the medicine, primarily limiting it to the adult population without any listed contraindications or functional impairments.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Ticlopidine is defined by its effects on hepatic metabolism and its additive impact on blood clotting, as documented in official regulatory labeling.

Pharmacodynamic and Pharmacokinetic Interactions

Co-administration with Warfarin or Heparin increases the risk of bleeding due to an additive effect on blood clotting. Similarly, Aspirin and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) potentiate the antiplatelet activity of Ticlopidine. These combinations require regulatory caution.

Ticlopidine is documented as reducing the clearance of other medicines processed by specific liver enzymes. Co-administration has been reported to significantly reduce the total plasma clearance of Theophylline and lead to elevated plasma levels of Phenytoin. Additionally, Ticlopidine reduces the clearance of Cimetidine by approximately 50%.

Exposure and Administration Constraints

Interaction Type	Interacting Substance	Official Regulatory Outcome
Drug-Food	Meal/Food Intake	Increases oral bioavailability by sim 20%
Drug-Drug	Antacids	Reduces Ticlopidine plasma levels by sim 18%
Condition-Specific	Severe Liver Dysfunction	Formally Contraindicated

Use is formally contraindicated in patients with severe liver dysfunction, a restriction based on the condition’s impact on drug metabolism. Anticoagulant drugs should be avoided as the safety of simultaneous administration with Ticlopidine has not been established in regulatory contexts.

Mechanism of Action

Irreversible Blockade of the P2Y12 Platelet Receptor

The mechanism of Ticlopidine is initiated by its active metabolite, which permanently disables the P2Y12 receptor, a primary sensor on the platelet surface for the aggregating agent ADP. By forming a covalent bond with this target, the drug establishes an irreversible antagonism that results in the functional inhibition of the platelet's response to activation signals.

Inhibition of the Aggregation Cascade

The blockade of the P2Y12 signal prevents the necessary internal process that leads to the activation of the Glycoprotein IIb/IIIa (GPIIb/IIIa) complex, the final molecular structure responsible for platelet-to-platelet adhesion via fibrinogen. This mechanism produces a systemic antiplatelet effect—a prolonged functional impairment of primary hemostasis—by inhibiting the platelet's final common pathway for aggregation.

⏳ Duration Tied to Platelet Turnover

Due to the permanent nature of the receptor inactivation, the duration of the antiplatelet effect is entirely independent of the drug's half-life and is instead governed by the biological lifespan of the affected platelets. The restoration of normal platelet function only occurs as the inhibited cells are naturally cleared and replaced by new, non-drug-exposed platelets (a process that takes approximately 7–10 days).

Dosage and Administration Information

How to Use Ticard

Ticard (Ticlopidine Hydrochloride) is an oral medication with specific administration requirements. This section details the standard usage patterns and procedural rules for taking the medicine, focusing strictly on administration instructions, not therapeutic outcomes or safety.

Official Administration Instructions

Category	Instruction
Route of Administration	The medication is taken orally (by mouth).
Standard Dosing Regimen	The standard adult dose is one 250 mg film-coated tablet taken twice a day (b.i.d.).
Timing in Relation to Meals	Ticard must be taken with meals. This instruction supports adequate absorption of the drug and helps to minimize potential gastrointestinal discomfort.
Missed Dose Rule	If a scheduled dose is missed, patients are instructed to skip the missed dose and resume the regular schedule. Doses should not be doubled to compensate.

Procedural Context and Time Course

Ticard is defined by a delayed onset of action. Consistent daily dosing is required because the drug's maximal antiplatelet effect is typically not established until approximately 8 to 11 days after therapy begins.

For instances when the medication must be stopped, such as prior to a surgical procedure, it is recommended to discontinue use 10 to 14 days beforehand. This specific duration allows the drug's influence on platelet function to fully subside, returning key functional parameters to normal levels. Use in pediatric patients is not established, as the safety and efficacy have not been demonstrated in that population.

Recent Clinical Evidence

Research evidence / Overview of Studies for Ticard

Evidence for Use in Preventing Vascular Events in Stroke and TIA

This section summarizes the research base, focusing on the large-scale Randomized Controlled Trials (RCTs) and meta-analyses that examined outcomes such as recurrent stroke and vascular death in the context of secondary prevention trials. Major randomized trials were conducted to compare Ticlopidine against a placebo and against Aspirin in adults who had previously experienced a TIA or ischemic stroke. The primary outcomes tracked were the incidence of fatal or nonfatal stroke and death from any cause. The major trials described patterns observed in the studies regarding the incidence of the primary composite outcome between the Ticlopidine group and the placebo group. Research that compared Ticlopidine against Aspirin explored whether differences in outcomes were observable, with some findings varying and others not reaching statistical significance.

Evidence for Use Following Coronary Stent Procedures

This section describes the body of research that evaluated the regimen of Ticlopidine, often in combination with aspirin, in the context of preventing blood clot formation (thrombosis) immediately after a coronary stent is placed. The outcomes monitored focused on the acute and subacute phases post-procedure, measuring the occurrence of a clot forming inside the stent (stent thrombosis) and the incidence of Major Adverse Cardiac Events (MACE). Early studies reported on patterns in the rate of stent thrombosis when comparing Ticlopidine/Aspirin regimens to older anticoagulation protocols. Subsequent comparative trials with newer antiplatelet agents reported similar patterns in the MACE outcome.

Long-Term Follow-up and Durability of Study Findings

While the major stroke prevention trials involved long-term follow-up lasting up to three years, data are still emerging regarding outcomes extending beyond this period. The research provides insight into short-term changes and intermediate-term patterns, but there is limited information for long-term outcomes, particularly concerning the durability of the observed findings over decades. For the post-stent context, follow-up durations were primarily focused on the short-term risk.

Areas of Uncertainty and Remaining Research Gaps

A key limitation is that much of the foundational evidence for Ticlopidine is older, having been established before many of the current standards of care were adopted. This means comparative evidence is lacking against the most recently developed antiplatelet agents. Additionally, some subgroup findings are uncertain, such as the direct comparison with Aspirin for all patient groups studied in stroke prevention. The follow-up durations were limited in many studies, meaning there is limited information for long-term outcomes beyond the intermediate term. The research provides context but not individual predictions for long-term use.

Frequently Asked Questions (FAQ)

Common questions about Ticard (FAQ)

Q: What is the main reason a doctor would prescribe Ticard?

Regulatory documents indicate that the medicine is prescribed to reduce the risk of thrombotic stroke (a stroke caused by a blood clot) in adult patients. This is typically for individuals who have already experienced a stroke precursor event (such as a TIA) or a completed thrombotic stroke. Its primary purpose is to reduce risk by helping to prevent blood platelets from sticking together.

Q: Is Ticard the same type of drug as other common medicines for its purpose?

No, Ticard is not the same as every other medicine used for this purpose. It is classified as a Platelet Aggregation Inhibitor, specifically belonging to the Thienopyridine class. This means it has a different way of working when compared to traditional anticoagulants or older antiplatelet agents like aspirin.

Q: Do I have to take Ticard long-term, or can I stop when I feel better?

Official product information emphasizes that the drug requires a consistent daily dosing schedule. The maximal antiplatelet effect is typically not established until approximately 8 to 11 days after treatment begins. For some medical procedures, official guidance states the medicine must be discontinued 10 to 14 days beforehand. This duration allows the drug's influence on platelet function to fully subside.

Q: Is it normal to feel tired or dizzy when starting Ticard?

Regulatory summaries indicate that dizziness is listed as a less common side effect associated with this medicine. While official documents do not explicitly list tiredness, individuals should be aware of potential drowsiness or dizziness that may occur.

Q: What should I know about Ticard and driving or operating machinery?

Regulatory documents indicate that because the medicine may cause dizziness or drowsiness, using caution with activities such as driving or operating machinery is appropriate. This is a common precaution for medications that may affect your alertness or coordination.

Q: Are there any major diet changes required while taking Ticard?

Regulatory instructions emphasize a key procedural requirement: the medication must be taken with meals to help the body absorb the drug adequately. Official documents do not detail major changes to specific food groups, but the medication must be taken with meals.

Q: Is Ticard a brand name or a generic name?

The active ingredient in the medication is Ticlopidine, which is the generic name for the substance. Ticard (or Ticlid) is a common brand name under which the product has been marketed.

Q: How does Ticard compare generally to other drugs in the same class?

Regulatory and pharmacological information classifies this medicine as a first-generation Thienopyridine derivative. It is generally noted that the drug may be reserved as a second-line therapy for patients who cannot tolerate or have had an insufficient response to other antiplatelet agents.

Q: Are there specific food items or drinks that interact with Ticard?

The official product information instructs that the medicine should be taken with meals for better absorption. Additionally, regulatory summaries advise that alcohol consumption should be avoided as it may increase the risk of stomach or intestinal bleeding due to the drug’s antiplatelet activity.

Q: Is Ticard an antidepressant or anxiety medication?

No. Official documents confirm that the medicine is classified as a Platelet Aggregation Inhibitor (an antiplatelet agent). It belongs to the class of drugs used to prevent blood clots and is not used to treat depression or anxiety.

Q: Can I take other vitamins or supplements with Ticard?

Regulatory summaries advise caution with certain herbal supplements, such as Dan Shen, Ginseng, Garlic, and Ginkgo, which may potentially affect blood clotting or increase the risk of bleeding. Official summaries advise that the use of any supplement be discussed with a healthcare professional.

Q: How is Ticard eliminated from the body?

The drug is primarily metabolized (broken down) in the liver to become active and later eliminated. Official documents indicate that clearance is reduced, and caution is needed in patients with severe kidney impairment, suggesting that both the liver and kidneys play a role in its removal from the body.

Q: Do most people take Ticard at the same time every day?

Official guidance states that the standard adult dose is one tablet taken twice a day (b.i.d.). Consistent daily dosing is required to maintain the steady level of antiplatelet effect needed for the medicine's purpose.

Q: Does alcohol interact negatively with Ticard?

Regulatory summaries indicate that alcohol consumption may increase the risk of bleeding, particularly in the stomach or intestinal tract. Because the medicine affects blood clotting, combining it with alcohol may present an increased risk.

Q: What is the recommended period to use Ticard for the best results, based on evidence?

Studies that established the medicine’s primary benefit in stroke prevention involved patient follow-up lasting up to three years. Official documents do not define a specific, required duration for all users, but the evidence base reflects the outcomes observed during these intermediate-term periods.

Q: Will Ticard interact with common over-the-counter cold and flu medications?

Yes, there is an interaction risk. Official regulatory documents list Aspirin and other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) as interacting substances. These are common ingredients in many over-the-counter cold and flu preparations.

Q: How long do any temporary side effects of Ticard usually last?

Official information provides limited details on the duration of all temporary effects. However, it notes that dyspnea (shortness of breath) is often reported but is typically self-limiting, meaning it usually resolves without requiring discontinuation of treatment.

Q: What kind of relief or improvement can be realistically expected with Ticard?

The core function of the medicine, as described in official documents, is to reduce the risk of vascular blockages by helping to prevent blood platelets from sticking together. The expected outcome, based on clinical research, is a reduction in the incidence of recurrent stroke or other dangerous vascular events.

Q: What is the risk of a serious allergic reaction to Ticard?

Hypersensitivity (allergic reaction) and rash are listed as Uncommon side effects in official summaries. A known severe hypersensitivity to the drug is a formal contraindication for use, as noted in official regulatory information.

Q: Is it possible for Ticard to stop working over time?

Studies on the durability of the medicine's findings and its effectiveness over long periods are noted in the research summaries. The follow-up data extending beyond the three-year duration of the major clinical trials is currently limited.

Q: What are the main goals of Ticard treatment as described by health organizations?

Major health organizations describe the main goal of Ticard treatment as reducing the risk of dangerous vascular blockages. This is achieved by preventing blood platelets from adhering to one another and forming pathological blood clots inside arteries.

How should Ticard be stored and disposed of?

How to Store and Dispose of Ticard

Ticard (Ticlopidine Hydrochloride) must be stored and handled according to the specific conditions defined in official regulatory labeling to ensure product stability and safety.

Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature, between 15 C and 30 C (59 F and 86 F).
Protection	Keep in a tightly closed, light-resistant container. Must be protected from moisture and kept from freezing.
Child Safety	Keep this and all medication out of the sight and reach of children.

Disposal Instructions

Unused or expired Ticard should be discarded using a community drug take-back program if available. If a take-back program is not accessible, follow the regulatory guidance for household disposal: mix the medicine with an undesirable substance, place it in a sealed bag or container, and discard it in the trash. The medication must not be flushed down a sink or toilet.

Ticard